Literature DB >> 16934069

The RHCE allele ceCF: the molecular basis of Crawford (RH43).

Willy A Flegel1, Franz F Wagner, Qing Chen, Gloria Schlanser, Tom Frame, Connie M Westhoff, Marilyn K Moulds.   

Abstract

BACKGROUND: The Crawford antigen (RH43) was described in 1980. It occurred in African American people, as a low-prevalence Rhesus antigen, who were also VS+. STUDY DESIGN AND METHODS: Twelve blood samples were analyzed because of inquiries into discrepant reactions in routine anti-D typing. The RHCE alleles were determined by nucleotide sequencing from genomic DNA. The D epitope profile was determined with 60 monoclonal anti-D. The population frequency was estimated in four major US regional blood centers.
RESULTS: The novel RHce(W16C, Q233E, L245V) allele, dubbed ceCF, was found to be occurring in the cde haplotype as cause of the reactivity with the immunoglobulin M anti-D GAMA401. The ceCF phenotype expressed few D epitopes resembling but not matching the reaction patterns observed with other RhCE variants, like R0 (Har), ceRT, and ceSL. The frequency of the ceCF phenotype was 0.056 percent among African American persons and 0.007 percent in the general US population.
CONCLUSION: The novel RHce(W16C, Q233E, L245V) allele, which is a variant of the known ce(s) allele, RHce(W16C, L245V), occurs in a haplotype with the RHD deletion and represents the molecular basis of the Crawford antigen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934069     DOI: 10.1111/j.1537-2995.2006.00901.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

Review 1.  Molecular genetics and clinical applications for RH.

Authors:  Willy A Flegel
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

2.  RHD PCR of D-Negative Blood Donors.

Authors:  Franz F Wagner
Journal:  Transfus Med Hemother       Date:  2013-05-08       Impact factor: 3.747

3.  Rh alloimmunization in chronically transfused patients with thalassemia receiving RhD, C, E, and K matched transfusions.

Authors:  Sarah J Waldis; Stacey Uter; Donna Kavitsky; Cynthia Flickinger; Sunitha Vege; David F Friedman; Connie M Westhoff; Stella T Chou
Journal:  Blood Adv       Date:  2021-02-09

Review 4.  Red cell genotyping precision medicine: a conference summary.

Authors:  Gregory A Denomme; Waseem Q Anani; Neil D Avent; Gregor Bein; Lynne B Briggs; Razvan C Lapadat; Celina Montemayor; Maria Rios; Maryse St-Louis; Lynne Uhl; Silvano Wendel; Willy A Flegel
Journal:  Ther Adv Hematol       Date:  2017-09-13

5.  It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Authors:  S Gerald Sandler; Willy A Flegel; Connie M Westhoff; Gregory A Denomme; Meghan Delaney; Margaret A Keller; Susan T Johnson; Louis Katz; John T Queenan; Ralph R Vassallo; Clayton D Simon
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

Review 6.  DNA-based methods in the immunohematology reference laboratory.

Authors:  Marion E Reid; Gregory A Denomme
Journal:  Transfus Apher Sci       Date:  2011-01-22       Impact factor: 1.764

7.  RHCE*ceCF encodes partial c and partial e but not CELO, an antigen antithetical to Crawford.

Authors:  Christine Halter Hipsky; Christine Lomas-Francis; Akiko Fuchisawa; Marion E Reid; Marilyn Moulds; Joann Christensen; Pam Nickle; Sunitha Vege; Connie Westhoff
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

8.  RhCE protein variants in Southwestern Germany detected by serologic routine testing.

Authors:  Peter Bugert; Erwin A Scharberg; Christof Geisen; Inge von Zabern; Willy A Flegel
Journal:  Transfusion       Date:  2009-05-18       Impact factor: 3.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.